TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03370432

Intervention type: OTHER
Intervention: Observational
Description: Information on diet, lifestyle, weight, height, medical treatment, environmental exposures, and other socio-economic factors were collected at enrolment using questionnaires and interviews

Intervention type: OTHER
Intervention: Observational
Description: Information on diet, lifestyle, weight, height, medical treatment, environmental exposures, and other socio-economic factors were collected at enrolment using questionnaires and interviews
Study: NCT00606593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-078573 oral capsules at 25 and 100 mg and matching placebo
Description: 5-period, 5-treatment crossover: sequences: ABECD, BCADE, CDBEA, DECAB, EADBC DCEBA, EDACB, AEBDC, BACED, CBDAE Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-078573 and matching placebo
Description: ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-078573 and matching placebo
Description: ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-078573 and matching placebo
Description: ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-078573 and matching placebo
Description: ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-078573 and matching placebo
Description: ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-078573 and matching placebo
Description: ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-078573 and matching placebo
Description: ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-078573 and matching placebo
Description: ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-078573 and matching placebo
Description: ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
Study: NCT04976543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nadroparin calcium-warfarin sequential anticoagulation
Description: The NWS therapy group were given a subcutaneous injection of nadroparin calcium every 12 hours for 1 month and switched to warfarin for 5 months. Warfarin was initiated at least 5 days before nadroparin calcium was stopped. International normalized ratio (INR) was detected every 3-4 days and adjusted carefully by 0.75mg dosage until achieve the target level of 2-3.
Study: NCT03068585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neovasculgen (Cambiogeneplasmid)
Description: treatment
Study: NCT03174730

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Growth Mindset
Description: The intervention is aimed at creating more flexible thinking about addiction to tobacco. Participants will be sent tips by email to help foster the belief that people can overcome addiction to smoking.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: SmartQuit
Description: This is an Acceptance and Commitment Therapy based intervention designed a smoking cessation smartphone application.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SmartQuit
Description: This is an Acceptance and Commitment Therapy based intervention designed a smoking cessation smartphone application.
Study: NCT00992797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: Cholecalciferol 200.000 IU pr ampoule, 400.000 IU given at randomization day, followed by additionally 200.000 IU at week 5 if serum 25(OH)D \< 100 nmol/L. If serum 25(OH)D \> 100 placebo will be given. The cholecalciferol will be given in orange juice.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Orange juice
Description: Orange juice at randomization day and at week 5.
Study: NCT03830619

Intervention type: DIAGNOSTIC_TEST
Intervention: collect samples
Description: collect serum samples and clinical features

Intervention type: DIAGNOSTIC_TEST
Intervention: collect samples
Description: collect serum samples and clinical features
Study: NCT02189733

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Caplacizumab
Description: Comparison of reconstituted lyophilised formulation versus liquid formulation of caplacizumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Caplacizumab
Description: Comparison of reconstituted lyophilised formulation versus liquid formulation of caplacizumab
Study: NCT03358264

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-citrulline
Description: Amino acid supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-citrulline
Description: Amino acid supplement
Study: NCT01707199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate + Sulphadoxine-pyrimethamine
Description: AS+SP will be administered according to the patient's age, based on a dose of 4mg artesunate/kg body weight once daily for 3 days plus SP at a dose of 25mg sulphadoxine/kg body weight single dose on the first day.~One co-blister pack of Artecospe will be used per patient and obtained via WHO from Guilin Pharmaceutical Co. Ltd., Shanghai China, with appropriate expiry date.
Study: NCT02422459

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COMMENCE
Description: ChrOnic pain self-ManageMent support with pain science Education and exerCisE (COMMENCE) consists of two visits with a physiotherapist per week over six weeks. One of the two visits is in a group setting, where the emphasis is on pain neurophysiology education and provision of self-management strategies. The second visit each week is an individualized, one-to-one session in which the focus is on providing support for implementing self-management strategies and developing of an individualized, goal-oriented exercise program.
Study: NCT03990727

Intervention type: DIAGNOSTIC_TEST
Intervention: Retina Analysis-mosaic
Description: Fundus retina pattern study

Intervention type: DIAGNOSTIC_TEST
Intervention: Retina Analysis-mosaic
Description: Fundus retina pattern study

Intervention type: DIAGNOSTIC_TEST
Intervention: Retina Analysis-mosaic
Description: Fundus retina pattern study

Intervention type: DIAGNOSTIC_TEST
Intervention: Retina Analysis-mosaic
Description: Fundus retina pattern study

Intervention type: DIAGNOSTIC_TEST
Intervention: Autofluorescence
Description: Fundus reflectance-functionality

Intervention type: DIAGNOSTIC_TEST
Intervention: Autofluorescence
Description: Fundus reflectance-functionality

Intervention type: DIAGNOSTIC_TEST
Intervention: Autofluorescence
Description: Fundus reflectance-functionality

Intervention type: DIAGNOSTIC_TEST
Intervention: Autofluorescence
Description: Fundus reflectance-functionality

Intervention type: DIAGNOSTIC_TEST
Intervention: OCT- 1 micra
Description: Fine tomography fundus retina

Intervention type: DIAGNOSTIC_TEST
Intervention: OCT- 1 micra
Description: Fine tomography fundus retina

Intervention type: DIAGNOSTIC_TEST
Intervention: OCT- 1 micra
Description: Fine tomography fundus retina

Intervention type: DIAGNOSTIC_TEST
Intervention: OCT- 1 micra
Description: Fine tomography fundus retina

Intervention type: PROCEDURE
Intervention: Genotype analysis
Description: Molecular target retina dystrophy analysis

Intervention type: PROCEDURE
Intervention: Genotype analysis
Description: Molecular target retina dystrophy analysis

Intervention type: PROCEDURE
Intervention: Genotype analysis
Description: Molecular target retina dystrophy analysis

Intervention type: PROCEDURE
Intervention: Genotype analysis
Description: Molecular target retina dystrophy analysis
Study: NCT04788706

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low level Laser Therapy and Russian electrical stimulation
Description: LLLT over three weeks followed by an eight-week receiving Russian electrical stimulation

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Laser and Russian electrical stimulation
Description: Placebo laser over three weeks followed by an eight-week receiving Russian electrical stimulation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low level Laser Therapy and Low level Laser Therapy plus Russian electrical stimulation
Description: LLLT over three weeks followed by an eight-week receiving LLLT application combined with Russian electrical stimulation

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Laser and Placebo Laser plus Russian electrical stimulation
Description: Placebo laser over three weeks followed by an eight-week receiving Placebo laser application combined with Russian electrical stimulation
Study: NCT00973232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DDS-06C (650 mg acetaminophen and 75 mg tramadol HCl)
Description: DDS-06C (650 mg acetaminophen and 75 mg tramadol HCl: two tablets, single dose, total administered of 1300 mg acetaminophen/150 mg tramadol HCl under fasting conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DDS-06C (650 mg acetaminophen and 75 mg tramadol)
Description: DDS-06C (650 mg acetaminophen and 75 mg tramadol HCl: two tablets, single dose, total administered of 1300 mg acetaminophen/150 mg tramadol HCl under fed conditions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zaldiar®
Description: Zaldiar® (325 mg acetaminophen and 37.5 mg tramadol HCl): two tablets; dose of 650 mg acetaminophen/75 mg tramadol HCl administered at Time = 0 hr (fasting)and second dose at Time = 6 hr (fed) Ultracet® (325 mg acetaminophen and 37.5 mg tramadol HCl)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ultracet®
Description: Ultracet® (325 mg acetaminophen and 37.5 mg tramadol HCl)two tablets; dose of 650 mg acetaminophen/75 mg tramadol HCl administered at Time = 0 hr (fasting)and second dose at Time = 6 hr (fed) Ultracet® (325 mg acetaminophen and 37.5 mg tramadol HCl)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Two tablets of DDS-06C (650 mg acetaminophen and 75 mg tramadol HCl), multiple doses, under both fed and fasting conditions
Description: Two tablets of DDS-06C, twice daily at 12-hour intervals under fed conditions for the first 4 days, then under fasting conditions for the 5th day. The total daily dose administered was 2600 mg Acetaminophen/300 mg tramadol HCl

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zaldiar®, multiple doses,(fed & fasting):
Description: Two tablets of Zaldiar®, 4 times daily at 6-hour intervals under fed conditions for the first 4 days, then under fasting conditions for the 5th day. The total daily dose administered was 2600 mg Acetaminophen/300 mg tramadol HCl

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ultracet®, multiple doses, (fed & fasting)
Description: Two tablets of Ultracet®, 4 times daily at 6-hour intervals under fed conditions for the first 4 days, then under fasting conditions for the 5th day. The total daily dose administered was 2600 mg Acetaminophen/300 mg tramadol HCl
Study: NCT01367990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: The occipital scalp zone at risk for alopecia will be identified. The norepinephrine treatment site will be randomized to receive consistent treatment of one half of the scalp risk zone. Approximately 1.6 mL of a 400 mM norepinephrine solution will be applied topically to the norepinephrine site approximately 20 minutes prior to each radiation treatment, and placebo will be applied to the contralateral side (30-35 treatments).
Study: NCT04315064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment with MTX110
Description: Patients will undergo surgery for maximum safe tumor resection with simultaneous placement of a ventricular access device (VAD) into the fourth ventricle or posterior fossa tumor resection cavity.The specific ventricular access device that will be placed is Medtronic Reference number 44102, Medtronic CSF-Ventricular Reservoir Side Inlet, 18 mm.If a patient already has a ventricular access device in place and additional tumor resection is not required, then that patient can proceed with intraventricular chemotherapy infusions after study enrollment. If the patient has metastatic disease in the brain and/or spine without resectable tumor in the posterior fossa, then only catheter and ventricular access device placement will be performed.Enrolled patients will receive 4 infusions per week of panobinostat (MTX110; 0.25 ml of 300 μM = 26.2 μg), per infusion into the ventricular access device for 6 consecutive weeks for a total of 24 infusions.
Study: NCT02186418

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: ARU-1801
Description: Autologous CD34+ hematopoietic stem cells transduced ex-vivo with a gamma-globin lentiviral vector~* Subjects with sickle cell anemia will undergo hematopoietic stem cell procurement by bone marrow harvest or apheresis after mobilization with plerixafor~* Reduced intensity chemotherapy conditioning with single dose melphalan will be used to facilitate engraftment of ex-vivo transduced cells.
Study: NCT01237197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: Exenatide 5 micrograms (mcg) twice per day (BID) for one month; up-titrated to 10 mcg twice per day for remainder of study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Exenatide
Description: Exenatide 5 micrograms (mcg) twice per day (BID) for one month; up-titrated to 10 mcg twice per day for remainder of study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants were randomized to a placebo injection for the first three months, then given open-label Exenatide for the remaining three months (Initiated at 5 mcg, twice per day, delivered by subcutaneous injection. After 1 month, exenatide was uptitrated to 10 mcg, twice per day for the remaining 2 months of the drug treatment phase).
Study: NCT00026169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT04282408

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scoliosis back brace
Description: The patients will use the traditional brace, if not already in use, for 2 weeks and then they will wear a 3D printed back brace for the following 2 weeks. Both the braces will be worn for the amount of hours per day prescribed by the physician.
Study: NCT02105181

Intervention type: DEVICE
Group type: OTHER
Intervention: Placement of a FCMS in the biliary tract of the patients
Description: During an ERCP procedure, a fully covered biliary metal stent (FCMS) is placed across a benign biliary stricture
Study: NCT00909298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTP889
Description: 300 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02198118

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Domiciliary exercises for the upper limbs
Description: Study group (SG) instructed to perform domiciliary exercises for the upper limbs.
Study: NCT02490865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RNS60
Description: RNS60, 4 ml dose nebulized twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal Saline, 4 ml dose nebulized twice daily
Study: NCT00983658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: huMAb OX40L
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Intravenous repeating dose
Study: NCT03000660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax at one of four escalating doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 20mg by mouth on days 1, 8, 15, and 22 of each cycle.
Study: NCT03761368

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote Ischemic Preconditioning
Description: four cycles of 5-min inflation to 200 mmHg followed by 5-min deflation of left upper - arm cuff

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Remote Ischemic Preconditioning
Description: deflated cuff placed on the left arm for 40 min
Study: NCT00749853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: follicle stimulating hormone
Description: Pituitary down-regulation will be achieved using buserelin (Suprefact®, Hoechst, Frankfurt, Germany) at a fixed daily dose of 200 mg s.c., according to a long agonist protocol, starting on day 2 of the normal menstrual cycle. Treatment with r-hFSH (Gonal-F®, Serono Austria GmbH, Vienna, Austria) will be started in women with serum E2 concentrations \<200 pmol/l and no follicles \>15 mm in diameter or ovarian cysts on ultrasonographic examination. The initial r-hFSH dose will be 250 IU s.c. daily for 5 days, after which the dose will be increased to a maximum of 450 IU per day using a step-up protocol with steps of 50 IU/day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: follicle stimulating hormone
Description: No pituitary down-regulation will be performed. Treatment with r-hFSH (Gonal-F®, Serono Austria GmbH, Vienna, Austria) will be started in women with serum E2 concentrations \<200 pmol/l and no follicles \>15 mm in diameter or ovarian cysts on ultrasonographic examination. The r-hFSH dose will be 150 IU s.c. daily for 11 consecutive days.
Study: NCT02645019

Intervention type: DEVICE
Intervention: Cuffed ETT
Description: Cuffed endotracheal tube.

Intervention type: DEVICE
Intervention: Cuffed LMA
Description: Cuffed laryngeal mask airway.

Intervention type: DEVICE
Intervention: Cuffed LMA
Description: Cuffed laryngeal mask airway.

Intervention type: DEVICE
Intervention: Cuffed LMA
Description: Cuffed laryngeal mask airway.

Intervention type: DEVICE
Intervention: Cuffed LMA
Description: Cuffed laryngeal mask airway.
Study: NCT02999204

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Two different doses of Vitamin D3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Two different doses of Vitamin D3
Study: NCT00882817

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary Rehabilitation
Description: The intervention group will perform a 6 month pulmonary rehabilitation program which consists of training, patient education, nutrition counseling and psychosocial support. They will be evaluated with some tests for the study.
Study: NCT01397968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YKP3089
Description: Capsule, dose to be titrated Tablet, dose to be titrated

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule Placebo tablet
Study: NCT02873351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carbidopa-levodopa 25-100 mg
Description: included in arm description

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo for carbidopa-levodopa 25-100 mg
Description: included in arm description
Study: NCT02162199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Debio 1450
Description: Single sentinel dosing of 40 mg per unit capsules is planned to escalate from 80 mg to 160, 320, 480, 640 and 800 mg, per respective dosing group. Doses may be modified based on review of available safety and pharmacokinetic (PK) data.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching single sentinel dosing of placebo capsules is planned to escalate from 2 capsules to 4, 8, 12, 16 and 20 capsules, per respective dosing group. The number of capsules will match those delivering Debio 1450 for the group, as those doses may be modified based on review of available safety and pharmacokinetic (PK) data.
Study: NCT01237769

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: 2200 IU/day

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle advice
Description: Diet and exercise
Study: NCT02905890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norethisterone enantate
Description: Noristerat® 200mg, solution for intramuscular injection given every 8 weeks

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Condoms
Description: Latex male condoms

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Condoms
Description: Latex male condoms
Study: NCT02515721

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pCLE-TB
Description: Patients will receive white-light endoscopic imaging, followed by probe-based Confocal Laser Endomicroscopy scanning on suspected lesions and 5 standardized locations. Then targeted Biopsies will be performed on locations with intestinal metaplasia, intraepithelial neoplasia, and carcinoma.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: virtual chromoendoscopy-TB
Description: Patients will receive virtual chromoendoscopy using iScan. Standard biopsies will be performed on all suspected lesions and standardized loctaions.
Study: NCT02340364

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education + Patient Navigation
Description: 208 patients randomized to self-care Education+ Patient Navigation-delivered self-care plan.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-care Education
Description: 208 patients randomized to self-care education alone.
Study: NCT02738385

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training
Description: Exercise will be performed at three sessions per week. All sessions will be supervised by a trained health or exercise professional.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderate Intensity Interval Training
Description: Exercise will be performed at three sessions per week. All sessions will be supervised by a trained health or exercise professional.